Guiding excipient selection for physically stable amorphous solid dispersions: A combined in-vitro in-silico approach
dc.contributor.author | Zeneli, Egis | |
dc.contributor.author | Bohets, Hugo | |
dc.contributor.author | Mebenga, Frédéric Ngono | |
dc.contributor.author | Holm, René | |
dc.contributor.author | Tistaert, Christophe | |
dc.contributor.author | Kuentz, Martin | |
dc.date.accessioned | 2025-07-18T09:30:53Z | |
dc.date.issued | 2025-06 | |
dc.description.abstract | Fast screening of amorphous solid dispersions (ASDs) is a need in the pharmaceutical industry. To support this, several emerging technologies have been developed ranging from in-silico prediction to miniaturized high-throughput experimentation. However, a notable challenge lies in the absence of comparative data. In the present work, a combination of a miniaturized screening of ASDs with calculation of activity coefficients using the conductor like screening model for real solvents (COSMO-RS) was proposed. First, the physical stability of ASDs comprising drugs of different glass forming ability (GFA) each with ten pharmaceutically relevant polymers was evaluated under accelerated stress conditions at two drug:polymer ratios. The miniaturized high-throughput screening method was based on the instability onset time that was monitored by polarized light microscopy (PLM). Furthermore, COSMO-RS was used to assess the interaction strength between the drugs and polymers by calculating activity coefficients, which was combined with estimations of the wet glass transition temperature (Tg), to account for molecular mobility. The computational calculations showed an overall alignment of 87 % with the instability of the ASDs observed experimentally for comparable drug:polymer ratios and humidity conditions. This positive result supports the current understanding of stable ASD formulation where at given ambient conditions, a low molecular mobility as well as the strength of interaction between drug and polymer has a main impact on the physical stability of ASDs. The current results are further encouraging to implement such a combined in-vitro/high-throughput (HTS) and in-silico strategy in early industrial screening of ASDs. | |
dc.identifier.doi | 10.1016/j.ejps.2025.107152 | |
dc.identifier.issn | 0928-0987 | |
dc.identifier.issn | 1879-0720 | |
dc.identifier.uri | https://irf.fhnw.ch/handle/11654/52129 | |
dc.identifier.uri | https://doi.org/10.26041/fhnw-13177 | |
dc.issue | 107152 | |
dc.language.iso | en | |
dc.publisher | Elsevier | |
dc.relation.ispartof | European Journal of Pharmaceutical Sciences | |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0/ | |
dc.subject | Amorphous solid dispersion | |
dc.subject | COSMO-RS | |
dc.subject | High-throughput screening | |
dc.subject | Physical stability | |
dc.subject.ddc | 600 - Technik, Medizin, angewandte Wissenschaften | |
dc.title | Guiding excipient selection for physically stable amorphous solid dispersions: A combined in-vitro in-silico approach | |
dc.type | 01A - Beitrag in wissenschaftlicher Zeitschrift | |
dc.volume | 212 | |
dspace.entity.type | Publication | |
fhnw.InventedHere | Yes | |
fhnw.ReviewType | Anonymous ex ante peer review of a complete publication | |
fhnw.affiliation.hochschule | Hochschule für Life Sciences FHNW | de_CH |
fhnw.affiliation.institut | Institut für Pharmatechnologie und Biotechnologie | de_CH |
fhnw.openAccessCategory | Gold | |
fhnw.publicationState | Published | |
relation.isAuthorOfPublication | d6f33532-1c7d-4762-a607-22389d33655e | |
relation.isAuthorOfPublication | 68819448-8611-488b-87bc-1b1cf9a6a1b4 | |
relation.isAuthorOfPublication | 1b06b83c-53f1-453c-accb-de685508ad8e | |
relation.isAuthorOfPublication.latestForDiscovery | 68819448-8611-488b-87bc-1b1cf9a6a1b4 |
Dateien
Originalbündel
1 - 1 von 1
Lade...
- Name:
- Guiding excipient selection for physically stable amorphous solid.pdf
- Größe:
- 3.64 MB
- Format:
- Adobe Portable Document Format
Lizenzbündel
1 - 1 von 1
Lade...
- Name:
- license.txt
- Größe:
- 2.66 KB
- Format:
- Item-specific license agreed upon to submission
- Beschreibung: